Ignite Creation Date:
2025-12-24 @ 4:12 PM
Ignite Modification Date:
2026-01-05 @ 1:55 PM
Study NCT ID:
NCT03622866
Status:
TERMINATED
Last Update Posted:
2021-03-11
First Post:
2018-07-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Algovita Spinal Cord Stimulation System Hi-Fi Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'submissionInfos': [{'resetDate': '2023-11-29', 'mcpReleaseN': 12, 'releaseDate': '2023-11-07'}], 'estimatedResultsFirstSubmitDate': '2023-11-07'}}, 'conditionBrowseModule': {'meshes': [{'id': 'D059350', 'term': 'Chronic Pain'}], 'ancestors': [{'id': 'D010146', 'term': 'Pain'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR'], 'maskingDescription': 'Subjects who receive a permanent implant will be randomly assigned in a 1:1 ratio to one of the two sequences of treatment. Randomization schedules for each site will be prepared by the contract research organization (CRO) statistician and uploaded into a role-limited module of the study database. In order to avoid any potential bias, each site will designate an unblinded coordinator (UC). The UC, Nuvectra field personnel (FP) and the CRO will be unblinded to the treatment group. The participant and other site staff will be blinded to the treatment group.'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'CROSSOVER', 'interventionModelDescription': 'During the Treatment Phase of the study, all subjects will receive both treatments under a crossover design. Subjects will undergo 12 weeks of treatment in each group with a 1-week washout between groups.'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 20}}, 'statusModule': {'whyStopped': 'Sponsor bankruptcy', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2018-11-02', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-03', 'completionDateStruct': {'date': '2020-04-27', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-03-09', 'studyFirstSubmitDate': '2018-07-26', 'studyFirstSubmitQcDate': '2018-08-07', 'lastUpdatePostDateStruct': {'date': '2021-03-11', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2018-08-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-04-27', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Effectiveness of targeted pain reduction compared to baseline in each treatment arm', 'timeFrame': 'Week 25', 'description': 'The percentage of participants who experience at least a 50 percent reduction in targeted pain from baseline, as assessed by Numeric Rating Scale (NRS). The Numeric Rating Scale (NRS) will range from 0 to 10 with a higher score indicating a higher level of pain.\n\nEffectiveness will be compared both descriptively and statistically between the two randomized treatment groups using crossover analysis methods.'}, {'measure': 'Rate of serious study-related adverse events (AEs) in each treatment arm', 'timeFrame': 'From Permanent Implant through Week 25', 'description': 'The rate of serious study-related AEs. Study-related AEs are defined as any device, procedure and therapy/stimulation-related AEs.'}], 'secondaryOutcomes': [{'measure': 'Effectiveness of targeted pain reduction compared to baseline in each treatment arm', 'timeFrame': 'Week 12 and Months 12, 18 and 24', 'description': 'The percentage of participants who experience at least a 50 percent reduction in targeted pain as assessed by Numeric Rating Scale (NRS). The Numeric Rating Scale (NRS) will range from 0 to 10 with a higher score indicating a higher level of pain.'}, {'measure': 'Effectiveness of back and/or leg pain reduction compared to baseline in each treatment arm', 'timeFrame': 'Weeks 12 and 25, and Months 12, 18 and 24', 'description': 'The percentage of participants who experience at least a 50 percent reduction in back and/or leg pain as assessed by Numeric Rating Scale (NRS). The Numeric Rating Scale (NRS) will range from 0 to 10 with a higher score indicating a higher level of pain.'}, {'measure': 'Effectiveness of targeted, back and/or leg pain reduction compared to baseline in each treatment arm', 'timeFrame': 'Weeks 12 and 25, and Months 12, 18 and 24', 'description': 'The percentage of participants who experience at least a 50 percent reduction in targeted, back and/or leg pain as assessed by a Visual Analog Scale (VAS). The Visual Analog Scale (VAS) will range from 0 mm (no pain) to 100 mm (worst pain imaginable). A higher score indicates a higher level of pain.'}, {'measure': 'Change in targeted, back and/or leg pain compared to baseline in each treatment arm', 'timeFrame': 'Weeks 12 and 25, and Months 12, 18 and 24', 'description': 'The mean change and percent change from baseline in targeted, back and/or leg pain as assessed by a Numeric Rating Scale (NRS). The Numeric Rating Scale (NRS) will range from 0 to 10 with a higher score indicating a higher level of pain.'}, {'measure': 'Change in targeted, back and/or leg pain compared to baseline in each treatment arm', 'timeFrame': 'Weeks 12 and 25, and Months 12, 18 and 24', 'description': 'The mean change and percent change from baseline in targeted, back and/or leg pain as assessed by a Visual Analog Scale (VAS). The Visual Analog Scale (VAS) will range from 0 mm (no pain) to 100 mm (worst pain imaginable). A higher score indicates a higher level of pain.'}, {'measure': 'Clinician Global Impression of Change score in each treatment arm', 'timeFrame': 'Weeks 12 and 25, and Months 12, 18 and 24', 'description': "The Investigator's assessment of change in the overall status of the participant using the standard Clinician Global Impression of Change ranging from 1 (very much improved) to 7 (very much worse)."}, {'measure': 'Change in disability compared to baseline in each treatment arm', 'timeFrame': 'Weeks 12 and 25, and Months 12, 18 and 24', 'description': 'The change from baseline in disability as measured by the Oswestry Disability Index. The Oswestry Disability Index is scored between 0 and 100 with higher scores indicating a greater disability.'}, {'measure': 'Change in quality of life compared to baseline in each treatment arm', 'timeFrame': 'Weeks 12 and 25, and Months 12, 18 and 24', 'description': 'The change from baseline in quality of life as measured by the EQ-5D-5L, a standardized measure of health status.'}, {'measure': 'Change in patient activity per the Pain Disability Index score in each treatment arm', 'timeFrame': 'Weeks 12 and 25, and Months 12, 18 and 24', 'description': 'The change from baseline in patient activity as measured by the Pain Disability Index score. The Pain Disability Index is a self-report asking participants to rate how much pain interferes in seven areas of life activity using a 0 (no disability) to 10 (total disability) numeric rating scale.'}, {'measure': 'Patient Global Impression of Change score in each treatment arm', 'timeFrame': 'Weeks 12 and 25, and Months 12, 18 and 24', 'description': "The participant's assessment of change in their overall status using the standard Patient Global Impression of Change ranging from 1 (very much improved) to 7 (very much worse)."}, {'measure': 'Participant satisfaction per the subject satisfaction survey outcome in each treatment arm', 'timeFrame': 'Weeks 12 and 25, and Months 12, 18 and 24', 'description': 'Participant satisfaction using a subject satisfaction survey (5 point Likert scale format) ranging from very satisfied to very dissatisfied.'}, {'measure': 'Evaluation of trial success rates', 'timeFrame': 'From Trial Implant to End of Trail', 'description': 'The percentage of participants that have a successful trial phase, defined as at least a 50 percent reduction in targeted pain compared to baseline.'}, {'measure': 'Rate of surgical re-intervention of the SCS system', 'timeFrame': 'From Permanent Implant through Month 24', 'description': 'Rate of surgical re-intervention of the SCS system for participants with a permanent implant.'}]}, 'oversightModule': {'isUsExport': True, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'conditions': ['Chronic Pain']}, 'descriptionModule': {'briefSummary': 'The objective of this study is to obtain post-market clinical outcome data for the Algovita SCS System when used on-label, according to the applicable directions for use, using high fidelity tonic stimulation at either ultra-high pulse width or traditional pulse width for the treatment of persistent or recurrent back and/or leg pain following spinal surgery.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patients with FBSS defined as persistent or recurrent back and/or leg pain despite one or more anatomically successful back surgeries for the same original pain.\n* Age 18-75 years old at consent.\n* Targeted pain intensity of ≥ 5 out of 10 on the Baseline visit NRS.\n* ODI score of 41-80 out of 100 at the Baseline visit.\n* Appropriate candidate for the surgical procedure and Algovita SCS therapy based on the clinical judgment of the investigator and the Algovita Instructions for Provider (IFP) in the Nuvectra product manuals.\n* On stable pain medications for at least 28 days prior to consent. Stable is defined as no new or discontinued pain medications and no changes to total daily dose of any pain medications.\n* Willing and capable of providing informed consent.\n* Willing and able of complying with the study-related requirements, procedures, and visits.\n* Speaks English as a primary language (as the Algovita patient manuals are only currently available in English).\n* Has adequate cognitive ability to use the subject devices (e.g., PPC, PoP), as determined by the investigator.\n\nExclusion Criteria:\n\n* Has a medical/psychological/psychiatric condition/disorder that could interfere with study procedures as determined by the investigator.\n* Has a coexisting pain condition that might confound pain ratings, as determined by the investigator.\n* Has a condition currently requiring or likely to require the use of MRI or diathermy.\n* Has an existing drug pump, SCS System, or other active implantable device.\n* Has any prior SCS experience.\n* Pregnant or planning to become (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile, or be at least 2 years postmenopausal).\n* For subjects with diabetes, HbA1c ≥ 8.5% as measured at the Baseline visit (or within the 3 months prior to the Baseline visit).\n* Participating in another clinical trial that could affect the outcomes or requirements of this study as determined by the investigator.\n* Involved in an injury claim under current litigation or have a pending or approved workers compensation claim.'}, 'identificationModule': {'nctId': 'NCT03622866', 'briefTitle': 'Algovita Spinal Cord Stimulation System Hi-Fi Study', 'organization': {'class': 'INDUSTRY', 'fullName': 'Nuvectra'}, 'officialTitle': 'Clinical Trial Comparing Ultra-High Versus Traditional Pulse Widths Using the ALGOVITA® SCS System High Fidelity Stimulation in the Treatment of Persistent or Recurrent Back and/or Leg Pain Following Spinal Surgery', 'orgStudyIdInfo': {'id': 'CLRE 1092'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Ultra-high pulse width', 'description': 'Ultra-high pulse width stimulation using the Algovita System', 'interventionNames': ['Device: Ultra-high pulse width stimulation']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Traditional pulse width', 'description': 'Traditional pulse width stimulation using the Algovita System', 'interventionNames': ['Device: Traditional pulse width stimulation']}], 'interventions': [{'name': 'Ultra-high pulse width stimulation', 'type': 'DEVICE', 'description': 'Algovita Spinal Cord Stimulation System with associated components', 'armGroupLabels': ['Ultra-high pulse width']}, {'name': 'Traditional pulse width stimulation', 'type': 'DEVICE', 'description': 'Algovita Spinal Cord Stimulation System with associated components', 'armGroupLabels': ['Traditional pulse width']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85712', 'city': 'Tucson', 'state': 'Arizona', 'country': 'United States', 'facility': 'Pain Institute of Southern Arizona', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'zip': '92660', 'city': 'Newport Beach', 'state': 'California', 'country': 'United States', 'facility': 'Newport Beach Headache & Pain', 'geoPoint': {'lat': 33.61891, 'lon': -117.92895}}, {'zip': '95401', 'city': 'Santa Rosa', 'state': 'California', 'country': 'United States', 'facility': 'Summit Pain Alliance', 'geoPoint': {'lat': 38.44047, 'lon': -122.71443}}, {'zip': '80919', 'city': 'Colorado Springs', 'state': 'Colorado', 'country': 'United States', 'facility': 'Spinal Diagnostics & Pain Management', 'geoPoint': {'lat': 38.83388, 'lon': -104.82136}}, {'zip': '66210', 'city': 'Overland Park', 'state': 'Kansas', 'country': 'United States', 'facility': 'Mid-America PolyClinic & Interventional Pain Management Specialists', 'geoPoint': {'lat': 38.98223, 'lon': -94.67079}}, {'zip': '71105', 'city': 'Shreveport', 'state': 'Louisiana', 'country': 'United States', 'facility': 'WK River Cities Clinical Research Center', 'geoPoint': {'lat': 32.52515, 'lon': -93.75018}}, {'zip': '02467', 'city': 'Chestnut Hill', 'state': 'Massachusetts', 'country': 'United States', 'facility': "Brigham & Women's Hospital", 'geoPoint': {'lat': 42.33065, 'lon': -71.16616}}, {'zip': '45601', 'city': 'Chillicothe', 'state': 'Ohio', 'country': 'United States', 'facility': 'Adena Spine Center', 'geoPoint': {'lat': 39.33312, 'lon': -82.9824}}, {'zip': '44195', 'city': 'Cleveland', 'state': 'Ohio', 'country': 'United States', 'facility': 'Cleveland Clinic Foundation', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '02903', 'city': 'Providence', 'state': 'Rhode Island', 'country': 'United States', 'facility': 'Comprehensive Spine Center at Rhode Island Hospital', 'geoPoint': {'lat': 41.82399, 'lon': -71.41283}}], 'overallOfficials': [{'name': 'Ben Tranchina', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Nuvectra'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Nuvectra', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Bright Research Partners', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}